AA
RXRX icon

ALPS Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

ALPS Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-156,214
Closed -$1.2M – 1006
2023
Q3 		$1.2M Buy
156,214
+14,818
+10% +$148K 0.01% 409
2023
Q2 		$1.06M Buy
141,396
+15,385
+12% +$108K 0.01% 481
2023
Q1 		$840K Buy
126,011
+2,846
+2% +$22.6K 0.01% 504
2022
Q4 		$950K Buy
123,165
+32,977
+37% +$323K 0.01% 489
2022
Q3 		$960K Sell
90,188
-12,102
-12% -$123K 0.01% 479
2022
Q2 		$833K Sell
102,290
-71,388
-41% -$478K 0.01% 504
2022
Q1 		$1.24M Sell
173,678
-10,936
-6% -$116K 0.01% 289
2021
Q4 		$3.16M Buy
+184,614
New +$3.47M 0.04% 191

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

ALPS Advisors's RXRX Position: Q4 2023 in Review

ALPS Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2023, closing a stake of 156,214 shares — an estimated $1.2M sold.

ALPS Advisors first reported a position in RXRX in Q4 2021 and held it in 8 quarters. The position peaked at $3.16M in Q4 2021. 199 funds tracked by Wall St. Rank hold RXRX as of Q4 2023.

  • ALPS Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • ALPS Advisors sold 156,214 Recursion Pharmaceuticals shares in Q4 2023, an estimated $1.2M.
  • ALPS Advisors first reported a position in Recursion Pharmaceuticals in Q4 2021 and held it in 8 quarters.
  • ALPS Advisors's Recursion Pharmaceuticals position peaked at $3.16M in Q4 2021.
  • 199 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2023.

Based on ALPS Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.